Moonlight AI, a Swiss diagnostic image-analysis startup, raised $3.3 million in private financing as it advances software that identifies genomic biomarkers and disease signatures from routine imaging of blood and cytology smears. The funding was led by Lotus One Investment, VP Venture Partners, and Medin Fund, with N&V Capital and QAI Ventures also participating. The company said it will use the capital to expand its library of whole-slide cytopathology images linked to genomic data with clinical partners, supporting the development and validation of diagnostic programs in myelodysplastic syndrome, non-small cell lung cancer, and chronic lymphocytic leukemia. Moonlight AI’s approach reflects continued investor appetite for image-to-biomarker systems that can leverage existing lab workflows rather than requiring entirely new testing modalities. Scaling the linked dataset and demonstrating reproducible clinical performance will likely be critical next steps. Funding size is modest relative to late-stage players, but it signals early-stage progress in an area where imaging infrastructure and molecular correlation can accelerate translation.